Introduction: Solving the clinical problem of vancomycin resistance

Clinical Infectious Diseases

Volumn 54, Issue SUPPL. 3, 2012, Pages

  Moellering, Robert C ^a   Ferraro, Mary Jane ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALBAVANCIN; METICILLIN; ORITAVANCIN; TEICOPLANIN; TELAVANCIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL CELL WALL; BACTERIAL MEMBRANE; BACTERIAL STRAIN; BINDING SITE; CHEMISTRY; DRUG ACTIVITY; DRUG MECHANISM; DRUG SYNTHESIS; EDITORIAL; GRAM POSITIVE BACTERIUM; HUMAN; NOCARDIA ORIENTALIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOMYCES; STREPTOMYCES ORIENTALIS;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84859035658     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir1046     Document Type: Editorial

References (11)

1. Moellering RC Jr. Vancomycin: a 50-year reassessment. Clin Infect Dis 2006; 42:S3-4.
2. Griffith RS. Introduction to vancomycin. Rev Infect Dis 1981; 3: S200-4.
3. Moellering RC Jr. Discovering new antimicrobial agents. Int J Antimicrob Agents 2011; 37:2-9.
4. Allen NE, Nicas TI. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol Rev 2003; 26:511-32.
5. Ge M, Chen Z, Onishi HR, et al. Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala. Science 1999; 284:507-11.
6. Patti GJ, Kim SJ, Yu TY, et al. Vancomycin and oritavancin have different modes of action in Enterococcus faecium. J Mol Biol 2009; 392:1178-91.
7. Lunde CS, Hartouni SR, Janc JW, Mammen M, Humphrey PP, Benton BM. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob Agents Chemother 2009; 53:3375-83.
8. Belley A, McKay GA, Arhin FF, et al. Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing. Antimicrob Agents Chemother 2010; 54:5369-71.
9. Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40:135-6.
10. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant Staphylococcus aureus infections among patients in the emergency department. N Engl J Med 2006; 355:666-74.
11. Ambrose PG, Drusano GL, Craig WA. In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans. Clin Infect Dis 2012; 54(Suppl 3):S220-8.